• This topic has 1 voice and 0 replies.
Viewing 0 reply threads
  • Author
    • #11876

      Scottish patients with pulmonary arterial hypertension (PAH) can now be treated with Actelion‘s Uptravi (selexipag) through the country’s National Health System (NHS) after a positive recommendation from the Scottish Medicines Consortium (SMC). However, the use of this therapy will be restricted to adult patients in WHO functional class 3 whose symptoms are not manageable or do not tolerate other available PAH therapies.

      Read more about this story here: Scottish Agency Recommends Uptravi for PAH Treatment Through National Health System


      Have you heard of selexipag? What do you think of this news?

Viewing 0 reply threads
  • You must be logged in to reply to this topic.

©2022 KLEO Template a premium and multipurpose theme from Seventh Queen


We're not around right now. But you can send us an email and we'll get back to you, asap.


Log in with your credentials


Forgot your details?

Create Account